Loading organizations...
§ Private Profile · 7 Halamish St, Caesarea, Haifa District, 38900, Israel
Remon Medical Technologies is a technology company.
Remon Medical Technologies develops smart, miniature implantable devices that utilize advanced wireless communication to monitor physiological parameters deep within the body. Their core product, the Remon™ ImPressure™, is an implantable hemodynamic monitor specifically designed for patients with congestive heart failure, enabling on-demand, non-invasive measurement of pulmonary artery pressure through proprietary acoustic technology. This technology facilitates wireless data and energy exchange with and between internal devices, allowing for continuous, passive monitoring.
The company was co-founded in 1997 by Dr. Eyal Doron, Dr. Yariv Porat, and Mr. Yoseph Tsaliah. Their collective insight stemmed from recognizing the unmet need for effective, non-invasive long-term monitoring within the human body, leading them to apply their scientific and engineering expertise to create solutions for remote patient management. They originated with a vision to transform how critical internal biometrics are accessed and analyzed.
Remon Medical's products primarily serve patients requiring chronic physiological monitoring, with clinicians being the direct users of the data for treatment decisions. The company's overarching vision is to enable physicians to non-invasively assess and treat a variety of medical conditions, leading to earlier intervention and improved disease management. This foundational technology also holds potential for broader applications in nerve stimulation, localized drug delivery, and post-operative care.
Remon Medical Technologies has raised $36.0M across 3 funding rounds.
Remon Medical Technologies has raised $36.0M in total across 3 funding rounds.
Remon Medical Technologies has raised $36.0M across 3 funding rounds. Most recently, it raised $10.0M Series C in January 2005.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2005 | $10M Series C | — | Polaris Partners | Announced |
| Sep 1, 2004 | $16M Series C | — | Polaris Partners | Announced |
| May 1, 2001 | $10M Series A | — | Polaris Partners | Announced |
Remon Medical Technologies has raised $36.0M in total across 3 funding rounds.
Remon Medical Technologies's investors include Polaris Partners.
Remon Medical Technologies was a development-stage company that developed and commercialized smart, miniature implants enabling physicians to assess and treat medical conditions non-invasively.[1][2][3] Its platform supported patient management, post-operative monitoring, nerve and tissue stimulation, local drug delivery, and drug development, with applications in cardiac rhythm management via wireless sensor and communication technology.[1][2] The company raised $10M before being acquired by Boston Scientific in 2007, integrating its innovations into a major medtech portfolio.[1][2]
Serving physicians and patients needing remote monitoring and therapy, Remon addressed challenges in invasive diagnostics and treatments by enabling intra-body wireless data exchange and energy transfer for physiological monitoring and stimulation.[2] While specific post-acquisition growth metrics are unavailable, its technology complemented Boston Scientific's cardiac products, positioning it for broader adoption in CRM markets.[2]
Founded in 1997 in Caesarea, Israel, Remon Medical Technologies focused on communication technology for medical devices from inception.[2] The company progressed as a development-stage firm, securing a co-development agreement with Guidant Corporation in 2004—prior to Guidant's acquisition by Boston Scientific in 2006.[2] This partnership marked early traction, leading to Boston Scientific's definitive acquisition agreement announced on June 25, 2007, which closed later that summer after due diligence.[2]
Leadership included CEO Hezi Himelfarb, who highlighted the years spent refining miniature implants for non-invasive applications.[2] The pivotal acquisition moment humanized Remon's journey, transitioning it from a standalone innovator to a key asset in Boston Scientific's CRM advancements.[2]
Remon filed 23 patents, underscoring its IP strength in implant tech.[1]
Remon rode the early 2000s wave of wireless medical implants and remote patient monitoring, aligning with trends in minimally invasive cardiology and CRM amid rising chronic disease burdens.[2] Timing was ideal post-Guidant partnership (2004) and amid Boston Scientific's 2006 acquisition spree, capitalizing on medtech consolidation and demand for sensor-driven therapies.[2]
Market forces favoring Remon included advances in microelectronics for intra-body comms, enabling scalable applications in drug delivery and stimulation—areas still expanding today.[1][2] Post-acquisition, its tech influenced Boston Scientific's ecosystem by enhancing CRM innovations, contributing to the evolution of connected implants in cardiac care.[2]
Remon's legacy endures through Boston Scientific's CRM portfolio, where its wireless tech likely advanced non-invasive monitoring devices over the past 18 years. Next steps involve ongoing integration into evolving medtech like AI-enhanced sensors and bioelectronics. Trends such as remote telemetry growth and miniaturization will amplify its foundational impact, potentially shaping next-gen implants for heart failure and beyond—solidifying its role from startup innovator to enduring medtech enabler.[2]